Josefine Bostner

List of Publications by Year
in descending order

10 papers	261 citations	1307594 7 h-index	1372567 10 g-index
10 all docs	10 docs citations	10 times ranked	553 citing authors

#	Article	IF	Citations
1	Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Research and Treatment, 2013, 137, 397-406.	2.5	82
2	Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer. Clinical Cancer Research, 2010, 16, 1624-1633.	7.0	55
3	ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 1421-1431.	7.0	44
4	Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis. PLoS ONE, 2015, 10, e0145013.	2.5	25
5	S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts. Endocrine-Related Cancer, 2015, 22, 331-343.	3.1	24
6	Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2018, 168, 17-27.	2.5	12
7	Ephrin–B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis–free survival in breast cancer. International Journal of Oncology, 2019, 55, 1275-1286.	3.3	8
8	RAB6C is an independent prognostic factor of estrogen receptor–positive/progesterone receptor–negative breast cancer. Oncology Letters, 2020, 19, 52-60.	1.8	5
9	Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor–positive/progesterone receptor–negative breast cancer. Molecular and Clinical Oncology, 2020, 12, 415-420.	1.0	4
10	IP6K2 predicts favorable clinical outcome of primary breast cancer. Molecular and Clinical Oncology, 2021, 14, 94.	1.0	2